Table 1.
Examples of clinical trials using VOA
| Clinical trial no. | Intervention | Key finding | References |
|---|---|---|---|
| NCT01319383 | Vorinostat (single dose) 8 patients | Single dose of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM | [26] |
| NCT01319383 | Vorinostat (multiple doses 3 ×/week for 8 weeks) 5 patients | Increase in cell-associated RNA with multiple doses compared to single dose of vorinostat in 3/5 patients, no reduction in IUPM | [27] |
| NCT01319383 | Vorinostat (multiple doses) 16 patients | Multiple doses of vorinostat increased cell-associated RNA in resting CD4 cells but no reduction in IUPM | [28] |
| NCT01680094 | Panobinostat 15 patients | Increase in cell-associated RNA, increase in plasma viraemia, no significant reduction in total and integrated DNA or IUPM. No delay in time to rebound in the 9 patients undergoing planned treatment interruption. | [29] |
| NCT00289952 | Valproic acid and ART 56 patients | No reduction in IUPM | [30] |
| NCT01286259 | Disulfiram 16 patients | Transient increase in plasma viraemia in a subset of patients, no overall change in plasma viraemia in the entire cohort, no change in IUPM | [31] |
| NCT02443935 | MGN1703 15 patients | Significant reduction in cell-associated RNA post-treatment, transient increase in plasma viraemia in 6/15 patients. No change in total or integrated HIV DNA, also no change in IUPM | [32] |
|
NCT02092116 REDUC |
Romidepsin, Vacc-4x and rhuGM-CSF 20 patients (17 completed trial) | Significant decrease (40%) in total DNA (in 16 patients measurable), non-significant decrease (19%) in integrated DNA (15 patients measurable) significant reduction (38%) in IUPM (6 patients measurable). No delay in time to rebound in the 15 patients who have undergone post treatment interruption | [19] |
| NCT02336074 RIVER | ART, Raltegravir, Vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv | Ongoing | |
| NCT02707900 VORVAX | Vorinostat and AGS-004 | Ongoing | |
|
NCT02471430 ACTIVATE |
Panobinostat and Pegylated Interferon-alpha2a | Ongoing | |
| NCT02408861 | Nivolumab and Ipilimumab | Ongoing |
IUPM infectious units per million cells as measured by VOA